Exchange: NASDAQ·Updated 04:10 PM EDT

ICCC News

News
all
press releases
ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2
ICCC's Q2 sales rise 11.5% y/y, but margins contract. A $2-million legal settlement boosts profit as the company plans a capacity expansion.
Zacks
More News
ImmuCell (ICCC) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand
ICCC reports an 11.5% rise in preliminary Q2 sales, driven by robust U.S. demand and improved product availability, extending the momentum from its strong Q1 performance.
Zacks
The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCell
Micron surged after strong Q3 results, robust AI-driven memory demand and a bullish Q4 outlook. See which ETFs have notable exposure.
Zacks
Top Stock Reports for JPMorgan, Novartis & Qualcomm
JPMorgan, Novartis and Qualcomm headline today's top stock reports, highlighting growth drivers, competitive pressures and key catalysts ahead.
Zacks
ICCC's Valuation Remains Premium: Is it Worth Overpaying for?
ImmuCell's premium valuation is backed by rising output, First Defense share gains and a sizable untapped calf-health market opportunity.
Zacks
ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand
ICCC posts record Q1 sales and 34% earnings growth as demand for its First Defense calf-health products boosts margins and market share.
Zacks
ImmuCell Q1 Earnings Call Highlights
ImmuCell Q1 Earnings Call Highlights...
Yahoo! Finance: News
Short Interest in ImmuCell Corporation (NASDAQ:ICCC) Decreases By 20.8%
ImmuCell Corporation (NASDAQ:ICCC - Get Free Report) saw a large decrease in short interest in the month of April. As of April 15th, there was short interest totaling 27,130 shares, a decrease of...
MarketBeat
ImmuCell (NASDAQ:ICCC) Stock Passes Above Two Hundred Day Moving Average - Should You Sell?
ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above Two Hundred Day Moving Average - Here's Why...
MarketBeat

Advertisement|Remove ads.